Format

Send to

Choose Destination
Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):305-15. doi: 10.1586/17474124.2015.965145. Epub 2014 Nov 6.

Biomarkers for early diagnosis of pancreatic cancer.

Author information

1
Department of Molecular and Clinical Cancer Medicine, National Institute for Health Research Liverpool Pancreas Biomedical Research Unit, University of Liverpool, Daulby Street, Liverpool L69 3GA, UK.

Abstract

Pancreatic ductal adenocarcinoma is an aggressive malignancy with a 5-year survival rate of approximately 5%. The lack of established strategies for early detection contributes to this poor prognosis. Although several novel candidate biomarkers have been proposed for earlier diagnosis, none have been adopted into routine clinical use. In this review, the authors examine the challenges associated with finding new pancreatic cancer diagnostic biomarkers and explore why translation of biomarker research for patient benefit has thus far failed. The authors also review recent progress and highlight advances in the understanding of the biology of pancreatic cancer that may lead to improvements in biomarker detection and implementation.

KEYWORDS:

biomarker; diagnosis; jaundice; pancreatic cancer

PMID:
25373768
DOI:
10.1586/17474124.2015.965145
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center